Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning

Citations

WEB OF SCIENCE

47
Citations

SCOPUS

46

초록

Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated considerable efficacy in the treatment of diabetes and obesity, it is essential to recognize that their use is associated with certain intrinsic risks that must not be disregarded. The incidence of adverse effects, particularly gastrointestinal complications, psychiatric disorders, and ocular problems, highlights the critical need for thorough patient assessment and continuous monitoring to ensure both the safety and effectiveness of treatment. Despite the possibility of adverse events, GLP-1 RAs continue to represent a crucial therapeutic modality for metabolic disturbances. This highlights the significance of ongoing research initiatives aimed at optimizing their safe utilization and refining current treatment protocols to improve patient outcomes. This review summarizes updated research findings regarding the adverse effects of GLP-1 RAs, their mechanisms of action, and guidelines for clinical application.

키워드

Biliary tract diseases; Drug-related side effects and adverse reactions; Eye diseases; Gastrointestinal diseases; Gluca-gon-like peptide-1 receptor agonists; Mental disorders; Pancreatic diseases; Sarcopenia; GLUCAGON-LIKE PEPTIDE-1; EVENT REPORTING SYSTEM; INCRETIN-BASED DRUGS; DIABETIC-RETINOPATHY; NO EVIDENCE; PANCREATITIS; EXENDIN-4; RISK; LIRAGLUTIDE; EXENATIDE
제목
Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
저자
Kim, Jung A.; Yoo, Hye Jin
DOI
10.4093/dmj.2025.0242
발행일
2025-07
유형
Article
저널명
Diabetes and Metabolism Journal
권
49
호
4
페이지
525 ~ 541